- Net sales amounted to TSEK 89 (TSEK 305)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,5 (MSEK -5,3)
-
Earnings per share after dilution at
SEK -0,09 (SEK 0,07 ) - Cash flow from operating activities amounted to TSEK -7 084 (TSEK -6 730)
- Liquid assets at the end of the period MSEK 13,4 (MSEK 4,7)
- Equity ratio was 82 % (77 %)
Summary of events during FIRST quarter
- An extra AGM was held 9 February.
Lars Johansson was elected Board Member and Chairman of the Board at the extra AGM.-
Wounds
UK publishes the peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel". The article concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity, in vitro, compared to other debridement products and techniques.
Summary of events after FIRST quarteR
- The
UK MHRA (Medicines & Healthcare products Regulatory Agency) has approved RLS' application to extend the current clinical study for pressure ulcers toUK . -
Eva Jagenheim leaves her role as CFO in
RLS Global AB . She will remain in service during her notice period, at latest to October, to ensure a smooth transition to her successor.
The Interim Report Q1, 2023, is enclosed and is also available at https://rls.global/financial-information/financial-reports-eng/
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on
TRADING PLACE AND CERTIFIED ADVISER:
FOR MORE INFORMATION, PLEASE CONTACT:
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO,
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57
ABOUT
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global
https://news.cision.com/rls-global-ab/r/rls-global-ab--publ--interim-report--q1--2023,c3777293
https://mb.cision.com/Main/12052/3777293/2094159.pdf
(c) 2023 Cision. All rights reserved., source